Kornimate/medical-research-clean huggingface dataset:
evaluation of salivary rna in subjects scheduled for surgery for a gynecologic pathology

Conditions: Gynecologic Disease; Gynecologic Cancer; Endometriosis; Ovarian Cancer; Cyst Ovary; Fibroid; Cervical Cancer; Uterine Cancer

Summary: gynran is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding rna contained in patients saliva. the study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females. the patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the local recommendations.


Eligibility criteria:
inclusion criteria: 1. subject of legal age (according to local legislation) and at least 18 years old 2. subject (and if applicable her legal representative) having dated and signed the informed consent form 3. subject with a medical insurance policy 4. subject presenting to the department: 1. with symptoms (bleeding and/or pain and/or clinically observed symptom) of one or more of the following pathologies (suspected undergoing diagnostic surgery/biopsy or diagnosed and before any curative treatment of the pathology): * endometriosis * adenomyosis, * ovarian cysts, * fibroids, * ovarian cancer, * cervical cancer, * uterine cancer. 2. asymptomatic with pap smear positive for cervical dysplasia or cervical cancer and before any curative treatment. 3. asymptomatic undergoing a pap smear for cervical cancer screening in a gynecological follow-up context. exclusion criteria: 1. recent (\<1 month) or ongoing bacterial or viral infection 2. known active oral or digestive mycosis 3. evolving oral pathology, symptomatic or obvious 4. known pregnancy 5. known current non-gynecological pelvic pathology 6. subject with a diagnosed breast cancer or cancer other than gynecological with the exception of basal cell carcinoma 7. subject with a history of treated cancer within the last 5 years with the exception of basal cell carcinoma 8. subject who has already received chemotherapy or radiotherapy or undergone complete or partial excision of the gynecological pathology of inclusion criterion 9. subject with significant difficulties reading or writing her language 10. subject unable to comply with study and/or follow-up procedures 11. participation in an interventional study with investigational drug or in the exclusion period of an interventional study.
more frequent dialysis (>3 treatments per week)

Conditions: End Stage Renal Disease; Chronic Kidney Disease

Summary: the study compares the benefits of short daily hemodialysis six days a week, nocturnal (night time) hemodialysis six days a week, every other day and every other night hemodialysis to traditional three days a week hemodialysis.the hypothesis is that increasing hemodialysis treatment time and/or frequency will improve outcomes.


Eligibility criteria:
inclusion criteria: * stable vascular access, i.e., lack of needling difficulties and stable flow rates. accesses will include fistulae, grafts, catheters and ports. * 18 years of age. * history of compliance with a dialysis treatment schedule, or if a new patient, express a willingness to be compliant with a treatment schedule. * plan to continue care and follow-up at the investigational site. * able to sign the informed consent and other relevant documents. exclusion criteria: * history of poor compliance with thrice (or twice) weekly dialysis schedules as manifested by more than three unexplained missed treatments in the past six (6) months. * pregnancy. * intravenous drug abuser. * expects to receive a transplant or transfer to another facility within six months of entering the study.

Keywords: hemodialysis adequacy frequency
text message study

Conditions: Anxiety; Pain; Surgical Site Infection

Summary: the objectives of this double-blind, randomized, controlled study are to evaluate the efficacy of maintaining contact with low-back pain patients through text messaging and emailing, to decrease anxiety levels, pain, number of follow-up visits through text messaging and emailing, and to improve reporting of surgical site infection after spine surgery through text messaging and emailing. the outcomes that will be measured are anxiety, pain, follow-up visits and received phone calls, and reporting signs of surgical site infection. participants will include dr. oren gottfried's patients who underwent spine surgery at duke hospital or at duke raleigh hospital. patients will be approached after determination that the patient is going to undergo spinal surgery. all patients meeting inclusion criteria will be approached to participate irrespective of race or ethnicity. a total of 194 subjects will be recruited.


Eligibility criteria:
inclusion criteria: * patients age greater than 18 years * patients who confirm they have an unlimited text message data plan and email capabilities on their mobile device * patients of dr. gottfried's underwent lumbar decompression or fusion surgery * patients with text message capabilities * patients who have an active email account exclusion criteria: * patients who demonstrate an inability to fill out the pre-visit questionnaires * patients with a diagnosis of metastatic disease * patients with workers compensation or liability pending * patients who will require transfer to an acute rehabilitation facility following surgery
clinical evaluation of eus-fna on diagnosis of pancreatic cystic lesions

Conditions: Pancreatic Cyst

Summary: it is still controversial about the necessity of endoscopy ultrasound guide fine needle aspiration (eus-fna) on diagnosis of pancreatic cystic lesions(pcl).the aim of this study is to find the influence of eus-fna on diagnosis and suggestions of eus specialists.

first, the investigators will send only eus images of patients with pcl to diagnosis committee that is consisted with 8 eus specialists from different countries.the diagnosis will be collected. then the investigators send the results of eus-fna. the diagnosis and suggestions will be collected again. the investigators will calculate how much diagnosis has been changed because of results of eus-fna. the investigators will also follow up these patients for 5 years at least to find if these patients benefit from eus-fna and complications such as needle tract seeding metastases.

Eligibility criteria:
inclusion criteria: 1. adults with ages from 18-80 years old. 2. the patients with pancreatic cystic lesions, which diameter of cystic lesion more than 2cm. 3. sign the informed consent voluntarily. - exclusion criteria: 1. the patient can't accept the endoscopic procedure. 2. the patient has blood coagulation dysfunction. 3. the patient has mental disorders. 4. the patient has mild or severe cardiorespiratory insufficiency. 5. the patient has hypertension and can't be controlled to safe level. 6. patients with alcohol dependence. 7. pregnant and lactating women. 8. the patients the investigators don't think suitable for this study. -

Keywords: eus-fna pancreatic cystic lesion diagnosis
immunogenicity and safety of 13-valent pneumococcal conjugate vaccine among hiv-infected adults

Conditions: Streptococcal Pneumonia; HIV/AIDS

Summary: hiv-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is still unclear. hiv-infected subjects aged ≥ 18 years were recruited and divided into two age-matched groups: group 1 (subjects with cd4 t-cell counts ≥350 cells/µl) and group 2 (subjects with cd4 t-cell counts \<350 cells/µl). multiplex opsonophagocytic killing assay was used to compare immunogenicity after the immunization of 13-valent pneumococcal conjugate vaccine (pcv13).

this single-center, open-label non-randomized clinical trial was conducted at korea university guro hospital from april 2015 to january 2017. based on the cd4 t-cell counts at the time of study enrollment, hiv-infected subjects aged ≥ 18 years were divided into two groups, group 1 (subjects with cd4 t-cell counts ≥350 cells/µl) and group 2 (subjects with cd4 t-cell counts \<350 cells/µl). the primary objective of the study was to demonstrate that the immune responses to pcv13 serotypes in group 2 (cd4 t-cell counts \<350 cells/µl) were not inferior to those in group 1 (cd4 t-cell counts ≥350 cells/µl) at one month after vaccination. in addition, the safety profiles of pcv13 were compared between two study groups. hiv-infected subjects aged ≥ 18 years with stable underlying diseases (≥ 4 weeks on haart) were eligible for this study. all available subjects with low cd4 t-cell counts (\<350 cells/µl, group 2) were recruited, and age/visit day-matched controls with high cd4 t-cell counts (≥350 cells/µl, group 1) were enrolled. the exclusion criteria were as follows: 1) a history of pneumococcal infection within the recent five years, 2) previous pneumococcal vaccination, 3) current opportunistic infections, 4) known immunodeficiency other than hiv infection and 5) coagulation disorders. the study was approved by the ethics committee of korea university guro hospital (irb no. 2014gr0014) and was conducted in accordance with the declaration of helsinki and good clinical practice. informed consent was taken for all participants before enrollment. venous blood samples of 10 ml were collected on day 0 and post-vaccination day 28 ± 7.

Eligibility criteria:
inclusion criteria: * hiv-infeted subjects who received antiretroviral therapy for ≥ 4 weeks exclusion criteria: * a history of pneumococcal infection within the recent five years * previous pneumococcal vaccination * current opportunistic infections * known immunodeficiency other than hiv infection * coagulation disorders
comparative effects of papworth technique versus pranayama in asthmatic patients

Conditions: Asthma

Summary: asthma is a chronic and heterogeneous disease characterized by reversible airway obstruction, airway inflammation and bronchial damage causing dyspnea, wheezing, chest tightness, coughing and impaired quality of life. papworth technique and pranayama modify the pattern of breathing to reduce the hyperventilation resulting in normalization of co2 levels, reduction of bronchospasm and resulting breathlessness .these techniques also change the emotional stresses, improve the immunity system and improve the strength /endurance of respiratory muscles. after taking the consent form from the participants, data will be collected from gulab devi chest hospital. non-probability convenience sampling will be applied on asthmatic patients according to inclusion criteria. patients will be allocated through simple random sampling into group a and b to collect data. group a will be treated by papworth technique. four weeks will be required to complete the treatment plan. three sessions will be given for one week so total 12 sessions will be given in one month. group b will be treated by pranayama. four weeks will be required to complete the treatment plan. three sessions will be given for one week so total 12 sessions will be given in one month. papworth technique and pranayama are used and are assessed to see their effectiveness in asthmatic patients by using four questionnaires on dyspnea, fatigue, anxiety, depression and quality of life. these four standardized questionnaires are borg dyspnea scale (bds), modified fatigue impact scale (mfis), hospital anxiety depression scale (hads) and asthma quality of life. pulse oximeter will be used to check the oxygen saturation. the study duration will be completed within time duration of 7 months.


Eligibility criteria:
inclusion criteria: * both genders(male and female) * age 20-40 years * patients with adverse mood effects * mild to moderate chronic asthma exclusion criteria: * acute severe asthma * chronic chest infections like tb * chest deformity * bronchiectasis * cardiac disease * substance abusers * chronic obstructive pulmonary disease * neurological disorders

Keywords: asthma, anxiety, papworth technique
a comparison of protein-bound and large molecular weight uremic toxin removals with novel super high-flux dialyzer between hemodialysis and high volume online hdf modalities

Conditions: Uremic; Toxemia

Summary: the goal of this prospective, randomized, crossover study is to study about using super high-flux dialyzer in the chronic hemodialysis patients. the main questions aim to answer are the reduction ratio of protein bound uremic toxins participants will undergone the pre-dilution online hemodiafiltration and conventional hemodialysis for each 8 weeks followed by washout phase for 4 weeks.

other secondary outcomes that the researcher wants to study are 1. the reduction ratio of beta2microglobulin, kappa and lambda free light chain 2. serum albumin and dialysate albumin loss 3. quality of life, muscle mass and nutritional status of the patients

Eligibility criteria:
inclusion criteria: * chronic hemodialysis patients in king chulalongkorn memorial hospital * residual renal function less than 100 ml/day exclusion criteria: * dialyzer allergy * malnutrition requiring intradialytic parenteral nutrition * cirrhosis child c or decompensated cirrhosis * active uncontrolled infection * active cardiovascular disease * advanced stage malignancy * predicted to be undergone living related kidney transplant within 1 year

Keywords: super high-flux dialyzers medium cut-off membrane protein bound uremic toxin indoxyl sulfate dialysate albumin loss albumin kappa free light chain lambda free light chain pre-dilution online hdf conventional hemodialysis
study of cancers after solid organs transplants

Conditions: Cancer; Organ Transplantation

Summary: about 1500 solid organs transplants are performed each year in the paris agglomeration. cancer risk in the transplanted is about three times higher than in a population of the same age without any organ transplant. thus cancer is an important problem for organ transplant. these cancers can be related to many factors : * post-transplant cancers are due in part to the non specific immunosuppression, which leads to oncogenic viruses replication, and then produces virus inducted cancers (as lymphoma due to ebv virus). * post-transplant cancers can also be due to the carcinogenic factors of the immunosuppressive drugs (as cyclosporine or tacrolimus, which can cause the appearance of metastases). however, a new type of immunosuppressive drugs (mtor inhibitors) appear to have anti-cancer properties. * post-transplant cancers which are not virus-inducted can be relied to genetic factors of the transplanted patient and/or the transplant donor. there are 4 axes in this study : * axis 1 : epidemiological, clinical and biological study of the incident cancers in transplanted patients. * axis 2 : qualitative and quantitative immunological study of lymphocyte cells by the transplanted patient (determine their characteristics when a cancer appears). * axis 3 : pathological and genetic study of the post-transplant cancer cells (see if the cancer is caused by the donor or the recipient). creation of a biobank. * axis 4 : pharmacogenetic study of the immunosuppressive drugs (determine the impact of patient genetic variability on tolerance and efficiency of the immunosuppressive drugs).

this is an observational and comparative study (2 control patients are recruited for each 1 case patient). a case patient is a patient who has developed a cancer after his/her transplant. a control patient is a patient who has not developed a cancer after his/her transplant. these 2 groups will be matched according to specific inclusion criteria.

Eligibility criteria:
inclusion criteria: * man or woman after 18 years old * transplanted with a solid organ (heart, kidney, lung,liver) * informed consent form signed * for the patients-case: patients who developed a post-transplant cancer * for the patients-control: patients who didn't develop a post-transplant cancer exclusion criteria: * cancer as transplant indication ( except liver ) * hiv positive

Keywords: organ transplant cancer biobank immunosuppressive drugs lymphoma
dapagliflozin patient satisfaction survey

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

this is a cross-sectional, observational patient survey study. study subjects will be adult commercial members of the large us health plan affiliated with optum with evidence of t2d initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Eligibility criteria:
inclusion criteria: * at least one pharmacy claim for dapagliflozin or dapagliflozin/metformin er in the most recent month of pharmacy data and no pharmacy claims for an sglt2 medication during the 6 months prior to sample identification. * evidence of t2d diagnosis. * age ≥18 as of the drug index date. * 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date. * self-reported t2d diagnosis during the patient interview. exclusion criteria: * patients with evidence of type 1 diabetes mellitus and unknown type * patients who are pregnant

Keywords: diabetes mellitus, type 2
postoperative pain management of therapeutic surgery: a prospective, observational cohort study.

Conditions: Postoperative Pain

Summary: poor management of post-operative acute pain can contribute to medical complications including pneumonia, deep vein thrombosis, infection and delayed healing, as well as the development of chronic. in contrast, appropriate pain control is capable of reducing the postoperative complications, preventing the development of chronic pain, and improving the quality of life. the workloads of medical staffs and health care cost are subsequently decreased. recently, a lot of analgesic methods have been developed and used in clinical practice, such as patient-controlled analgesia, ultrasound-guided long-term analgesia and multimodal analgesia. this study is aimed to investigate the outcome of each postoperative analgesic method used in china medical university hsinchu hospital. this real world data can serve as a reference toward high health care quality.

this is a prospective, observational, cohort study. patients undergoing elective surgery will be invited to the study. the written informed consent will be obtained prior to participation. demographic data, underlying condition, surgical procedures, consumption of anesthetics and analgesics, analgesic methods, postoperative complications, pain intensity and life quality will be collected from medical history and by questionnaires.

Eligibility criteria:
inclusion criteria: 1. aged 20 to 80. 2. needing pain management after elective surgery. 3. american society of anesthesiology physical class (asa) between 1 and 3. exclusion criteria: 1. allergic to anesthetics, opioids, or medicine used during study period. 2. severe comorbidity, such as cardiopulmonary disease and strock. 3. abuse or long-term use of opioids. 4. pregnant or breastfeeding. 5. judged to be unsuitable subjects by investigator.

Keywords: postoperative pain analgesics analgesia dinalbuphine sebacate naldebain pca extended-release
a study of 2-dose vaccine regimen using 3 consecutive lots of ad26.zebov and mva-bn-filo in adult participants

Conditions: Ebola

Summary: the purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (ad26.zebov) as dose 1 and 3 consecutively manufactured lots of modified vaccinia ankara bavarian nordic vector encoding multiple filovirus proteins (mva-bn-filo) including the ebola virus mayinga glycoprotein as dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.


Eligibility criteria:
inclusion criteria: * signed an informed consent form (icf) * medically stable in the investigator's clinical judgment on the basis of physical examination, medical history, and vital signs performed at screening * before randomization, a woman must be either: a. not of childbearing potential; b. of childbearing potential and practicing an acceptable effective method of birth control and agrees to remain on such a method of birth control from signing the informed consent form (icf) until at least 3 months post dose 1 vaccination or 28 days post dose 2 vaccination or 3 months post booster vaccination (groups 5-6 only), whichever comes later. use of hormonal contraception should start at least 28 days before the first administration of study vaccine. acceptable effective methods for this study include: 1) hormonal contraception; 2) intrauterine device (iud); 3) intrauterine hormone-releasing system (ius); 4) male or female condom with or without spermicide; 5) cap, diaphragm, or sponge with a vaginal spermicide; 6) vasectomized partner (the vasectomized partner should be the sole partner for that participant); 7) sexual abstinence * women of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hcg) pregnancy test at screening and immediately prior to each study vaccine administration * available and willing to participate for the duration of the study and follow-up visit * willing to provide verifiable identification exclusion criteria: * having received any candidate ebola vaccine * diagnosed with ebola virus disease (evd), or prior exposure to ebola virus, including travel to an area with ebola outbreak less than 1 month prior to screening (if applicable) * known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines), including known allergy to egg, egg products, and aminoglycosides * presence of acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0ºcelcius on day 1. participants with such symptoms will be excluded from enrollment at that time but may be rescheduled for enrollment at a later date * human immunodeficiency virus (hiv) type 1 or type 2 infection, based on the medical history reported by the participant * pregnant, breast-feeding * history of an underlying clinically significant acute or chronic medical condition